Eaton Corporation plc vs Cassava Sciences Inc — how do they compare? Eaton Corporation plc trades at $395.17 (market cap $160.31B), while Cassava Sciences Inc trades at $1.07 (market cap $53.14M). The key difference: Eaton Corporation plc is far larger — about 3016.7× Cassava Sciences Inc's market cap, and Eaton Corporation plc pays a 1.07% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| ETN | FLNA | |
|---|---|---|
Market Cap | $160.31B | $53.14M |
Sector | Technology | Health |
52-Week High | $435.78 | $4.64 |
52-Week Low | $315.82 | $1.09 |
Enterprise Value | $181.40B | -$33.43M |
Dividend Yield | 1.07% | — |
Signals from Pluang's Aura AI — not financial advice
Eaton (ETN) trades at $395.5, down 4.82% over 24 hours, but remains near its 52-week high. The stock shows a bullish technical trend with strong moving averages and support at $392. Fundamentally, the company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $2.81 exceeding the $2.73 estimate. Revenue for 2025 reached $27.45 billion, with a net income margin of 13.99%. Analyst sentiment is overwhelmingly positive, with a consensus price target of $449.50 and 64.1% of analysts rating it a Buy.
The outlook for ETN is favorable, driven by strong demand in data center power infrastructure and recent strategic acquisitions. However, risks include elevated valuation multiples like a P/E of 40.4 and potential macroeconomic pressures on industrial spending. The stock offers upside to the consensus target but requires monitoring of execution on growth initiatives and competitive dynamics in the power management sector.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Trailing returns across standard periods
Latest headlines on both assets
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →